FibroGen, Inc (FGEN): Price and Financial Metrics

FibroGen, Inc (FGEN): $2.35

0.23 (-8.91%)

POWR Rating

Component Grades

Momentum

C

Stability

F

Sentiment

Quality

C

Add FGEN to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#138 of 365

in industry

FGEN Price/Volume Stats

Current price $2.35 52-week high $20.90
Prev. close $2.58 52-week low $0.33
Day low $2.31 Volume 1,357,200
Day high $2.59 Avg. volume 2,633,203
50-day MA $1.93 Dividend yield N/A
200-day MA $1.95 Market Cap 232.11M

FGEN Stock Price Chart Interactive Chart >

FGEN POWR Grades

  • Growth is the dimension where FGEN ranks best; there it ranks ahead of 81.21% of US stocks.
  • FGEN's strongest trending metric is Growth; it's been moving up over the last 26 weeks.
  • FGEN's current lowest rank is in the Stability metric (where it is better than 0.7% of US stocks).

FGEN Stock Summary

  • Equity multiplier, or assets relative to shareholders' equity, comes in at -6.07 for FIBROGEN INC; that's greater than it is for only 3.35% of US stocks.
  • In terms of volatility of its share price, FGEN is more volatile than 99.21% of stocks we're observing.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for FGEN comes in at -220.35% -- higher than that of just 2.06% of stocks in our set.
  • Stocks that are quantitatively similar to FGEN, based on their financial statements, market capitalization, and price volatility, are EDIT, ONCT, FUSN, ITOS, and SLDP.
  • Visit FGEN's SEC page to see the company's official filings. To visit the company's web site, go to www.fibrogen.com.

FGEN Valuation Summary

  • In comparison to the median Healthcare stock, FGEN's price/sales ratio is 72.73% lower, now standing at 0.6.
  • Over the past 111 months, FGEN's EV/EBIT ratio has gone up 46.1.

Below are key valuation metrics over time for FGEN.

Stock Date P/S P/B P/E EV/EBIT
FGEN 2023-12-29 0.6 -0.6 -0.3 -0.6
FGEN 2023-12-28 0.6 -0.6 -0.3 -0.6
FGEN 2023-12-27 0.5 -0.5 -0.3 -0.6
FGEN 2023-12-26 0.5 -0.5 -0.3 -0.6
FGEN 2023-12-22 0.5 -0.5 -0.3 -0.6
FGEN 2023-12-21 0.4 -0.4 -0.2 -0.5

FGEN Growth Metrics

    The 2 year price growth rate now stands at -78.2%.
  • The 4 year net cashflow from operations growth rate now stands at -5702.49%.
  • Its 3 year cash and equivalents growth rate is now at 127.61%.
FGEN's revenue has moved down $134,204,000 over the prior 30 months.

The table below shows FGEN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 122.911 -148.38 -361.557
2022-06-30 263.149 -52.245 -220.109
2022-03-31 257.707 -45.724 -281.473
2021-12-31 235.309 -82.232 -290.023
2021-12-31 235.309 -82.232 -290.023
2021-09-30 283.765 -34.5 -214.579

FGEN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • FGEN has a Quality Grade of B, ranking ahead of 75.49% of graded US stocks.
  • FGEN's asset turnover comes in at 0.212 -- ranking 192nd of 681 Pharmaceutical Products stocks.
  • CKPT, ARWR, and IBIO are the stocks whose asset turnover ratios are most correlated with FGEN.

The table below shows FGEN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.212 0.934 -1.182
2021-03-31 0.235 0.941 -0.907
2020-12-31 0.216 0.950 -0.594
2020-09-30 0.145 0.940 -0.473
2020-06-30 0.128 0.952 -0.520
2020-03-31 0.295 0.992 -0.151

FGEN Price Target

For more insight on analysts targets of FGEN, see our FGEN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $24.71 Average Broker Recommendation 1.9 (Hold)

FibroGen, Inc (FGEN) Company Bio


Fibrogen is a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. The company was incorporated in 1993 and is based in San Francisco, California.


FGEN Latest News Stream


Event/Time News Detail
Loading, please wait...

FGEN Latest Social Stream


Loading social stream, please wait...

View Full FGEN Social Stream

Latest FGEN News From Around the Web

Below are the latest news stories about FIBROGEN INC that investors may wish to consider to help them evaluate FGEN as an investment opportunity.

FibroGen, Inc. (NASDAQ:FGEN) Q3 2023 Earnings Call Transcript

FibroGen, Inc. (NASDAQ:FGEN) Q3 2023 Earnings Call Transcript November 6, 2023 FibroGen, Inc. beats earnings expectations. Reported EPS is $-0.52, expectations were $-0.68. Operator: Hello and welcome to the FibroGen’s Third Quarter 2023 Earnings Call. At this time, all participants are in listen-only mode. After the speaker presentation, there will be a question-and-answer session. [Operator […]

Yahoo | November 7, 2023

Q3 2023 FibroGen Inc Earnings Call

Q3 2023 FibroGen Inc Earnings Call

Yahoo | November 7, 2023

FibroGen Inc (FGEN) Reports 155% YoY Increase in Q3 2023 Net Revenue

Strong Roxadustat Volume Growth in China and Successful Cost Reduction Plan Boosts Performance

Yahoo | November 6, 2023

FibroGen (FGEN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for FibroGen (FGEN) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Yahoo | November 6, 2023

FibroGen Reports Third Quarter 2023 Financial Results

Topline data from two pivotal pamrevlumab pancreatic cancer trials on track to read out in 1H 2024, including the Pancreatic Cancer Action Network (PanCAN) Precision PromiseSM Phase 2/3 study in metastatic pancreatic cancer Third quarter net revenue of $40.1 million, an increase of 155% year over year Roxadustat sNDA accepted in China for chemotherapy-induced anemia Robust roxadustat volume growth of 37% in ChinaStrong execution of cost reduction plan reaffirming cash runway into 2026 SAN FRANCI

Yahoo | November 6, 2023

Read More 'FGEN' Stories Here

FGEN Price Returns

1-mo 10.85%
3-mo 165.15%
6-mo 172.34%
1-year -87.92%
3-year -92.42%
5-year -95.68%
YTD 165.15%
2023 -94.47%
2022 13.62%
2021 -61.98%
2020 -13.52%
2019 -7.32%

Continue Researching FGEN

Here are a few links from around the web to help you further your research on Fibrogen Inc's stock as an investment opportunity:

Fibrogen Inc (FGEN) Stock Price | Nasdaq
Fibrogen Inc (FGEN) Stock Quote, History and News - Yahoo Finance
Fibrogen Inc (FGEN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!